secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2023-06-08T23:59:59+00:00
Accession:  0001104659-23-069137
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MedTech Acquisition raises $17.9M PIPE via Series A convertible preferred for TriSalus merger
--------------------------------------------------------------------------------

- Subscribers committed to purchase 1,785,502 shares of Series A Convertible Preferred Stock at $10/share, aggregate $17,855,020.
- Preferred shares convertible into common at $10, with an 8% annual dividend payable in cash or stock.
- Conversion price resets at 18 and 47 months post-close to VWAP, subject to a floor of $2.00.
- Backstop Letter Agreement with Sponsor commits to purchase any shortfall up to $2M if subscriber target not met.
- Closing is contingent upon and concurrent with the business combination closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923069137/0001104659-23-069137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465923069137/tm2317638d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-069137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer